Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
ASKA’s Oral Hysteromyoma Drug Shows Non-Inferiority to Leuprorelin in PIII
ASKA Pharmaceutical said on November 26 that ulipristal (development code: CDB-2914), which is in development as a hysteromyoma treatment, met its primary endpoint in a Japan PIII trial that compared its efficacy and safety to the injectable gonadotropin-releasing hormone (GnRH)…
To read the full story
Related Article
- ASKA Files Uterine Fibroid Drug in Japan
December 25, 2019
- ASKA, Laboratoire HRA Strike Deal for IP Rights to Uterine Fibroid Treatment
August 1, 2018
- ASKA Licenses Ulipristal from Laboratoire HRA
June 6, 2011
BUSINESS
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
- GNI Closes Acquisition of Ayumi Pharma
July 2, 2026
- Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…